INTERNATIONAL SEARCH REPORT

International application No.

PCT/US02/38414

A. CLASSIFICATION OF SUBJECT MATTER IPC(7) : C12N 15/00, 15/63, 15/74; C07H 21/00, 21/0	14; CO7K 16/00			
US CL : 536/23.1, 23.53; 435/320.1,325,455; 530/387.1, 387.3				
According to International Patent Classification (IPC) or to both	national classification and IPC			
B. FIELDS SEARCHED				
Minimum documentation searched (classification system followed U.S.: 536/23.1, 23.53; 435/320.1,325,455; 530/387.1, 387				
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched None				
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) Please See Continuation Sheet				
C. DOCUMENTS CONSIDERED TO BE RELEVANT				
Category * Citation of document, with indication, where a		Relevant to claim No.		
Y _ US 6,132,722 A (SIEMERS et al.) 17 October 200	00 (17.10.00), see entire document.	1-13, 15, 16, 18, 30,		
Y KERR. D.E. et al. Development and activities of a tumor-selective activation. Bioconj. Chem. 1998, V document.		27, and 30 1-13, 15, 16, 18, 20, 27, and 30		
Y KERR. D.E. et al. Comparison of Recombinant an antibody-b-lactamase conjugates for anticancer pro Vol. 10, pages 1084-1089, see entire document.		1-13, 15, 16, 18, 20, 27, and 30		
Y WORN. A. et al. Stability engineering of antibody Biol. 2001, Vol. 305, pages 989-1010, see entire d		1-13, 15, 16, 18, 20, 27, and 30		
·				
Further documents are listed in the continuation of Box C.	See patent family annex.			
Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the inter date and not in conflict with the applica principle or theory underlying the inven	tion but cited to understand the		
"B" cartier application or patent published on or after the international filing date	"X" document of particular relevance; the considered novel or cannot be consider			
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	when the document is taken alone "Y" document of particular relevance; the considered to involve an inventive step			
"O" document referring to an oral disclosure, use, exhibition or other means	combined with one or more other such being obvious to a person skilled in the			
"P" document published prior to the international filing date but later than the priority date claimed	"&" document member of the same patent f	omity		
Date of the actual completion of the international search	Date of mailing of the international sear	ch report		
30 June 2003 (30.06.2003) 28 JUL 2003				
Name and mailing address of the ISA/US Mail Stop PCT, Atm: ISA/US	Authorized officer This is a Reber	t for		
P.U. BOX 1430		00,		
Alexandria, Virginia 22313-1450 Facsimile No. (703)305-3230	Telephone No. 703-308-1235			

Form PCT/ISA/210 (second sheet) (July 1998)



Internacional application No.

PCT/US02/38414

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)		
This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:		
1.		Claim Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
2.		Claim Nos.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3.	6.4(a).	Claim Nos.: 14,17,19,21-26,28,29 and 31-33 because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule
Box	k II Ol	servations where unity of invention is lacking (Continuation of Item 2 of first sheet)
Thi	s Interna	tional Searching Authority found multiple inventions in this international application, as follows:
1. 2. 3.		As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. Rei	nark on	No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: Protest The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.

Form PCT/ISA/210 (continuation of first sheet(1)) (July 1998)

/ 	
· 	PCT/US02/50~14
INTERNATIONAL SEARCH REPORT	
	·
	1
	<u> </u>
1	
1	
	·
	•
,	
Continuation of D. ETEI DC CEA DCDED Itom 2.	
Continuation of B. FIELDS SEARCHED Item 3:	
DIALOG-Medime, Embase, Cancerlit, Scisearch, Biosis; BRS-EAST: USPathill	, PGPubs, EPO, JPO, Derwini
DIALOG-Medline, Embase, Cancerlit, Scisearch, Biosis; BRS-EAST:USPatfull search terms: L49, antibody, single chain antibody, scfv, sfv, modified, mutated	, PGPuos, EPO, JPO, Derwint I, fusion, fused, chimeric, adept
search terms: L49, antibody, single chain antibody, scfv, sfv, modified, mutated	, POPulos, EPO, IPO, Derwint I, fusion, fused, chimeric, adept
search terms: L49, antibody, single chain antibody, scfv, sfv, modified, mutated	, POPulos, EPO, 1PO, Derwini I, fusion, fused, chimeric, adept
search terms: L49, antibody, single chain antibody, scfv, sfv, modified, mutated	, POPulos, EPO, 1PO, Derwini I, fusion, fused, chimeric, adept
search terms: L49, antibody, single chain antibody, scfv, sfv, modified, mutated	, POPulos, EPO, 1PO, Derwini I, fusion, fused, chimeric, adept
search terms: L49, antibody, single chain antibody, scfv, sfv, modified, mutated	, POPulos, EPO, 1PO, Derwini I, fusion, fused, chimeric, adept
bialtog-medime, Embase, Cancerlit, Scisearch, Biosis; BRS-EAST: USPatfull, search terms: L49, antibody, single chain antibody, scfv, sfv, modified, mutated	, POPulos, EPO, 1PO, Derwin I, fusion, fused, chimeric, adept
bialtog-medine, Embase, Cancerlit, Scisearch, Biosis; BRS-EAST: USPatfull, search terms: L49, antibody, single chain antibody, scfv, sfv, modified, mutated	, POPulos, EPO, 1PO, Derwin I, fusion, fused, chimeric, adept
bialtog-medine, Embase, Cancerlit, Scisearch, Biosis; BRS-EAST: USPatfull, search terms: L49, antibody, single chain antibody, scfv, sfv, modified, mutated	, POPulos, EPO, 1PO, Derwin I, fusion, fused, chimeric, adept
bialtog-medine, Embase, Cancerlit, Scisearch, Biosis; BRS-EAST: USPatfull, search terms: L49, antibody, single chain antibody, scfv, sfv, modified, mutated	, POPulos, EPO, 1PO, Derwini I, fusion, fused, chimeric, adept
bialtog-medime, Embase, Cancerlit, Scisearch, Biosis; BRS-EAST: USPatfull, search terms: L49, antibody, single chain antibody, scfv, sfv, modified, mutated	, POPulos, EPO, 1PO, Derwing I, fusion, fused, chimeric, adept
bialtog-medine, Embase, Cancerlit, Scisearch, Biosis; BRS-EAST: USPatfull, search terms: L49, antibody, single chain antibody, scfv, sfv, modified, mutated	, POPulos, EPO, 1PO, Derwing I, fusion, fused, chimeric, adept
bialtog-medine, Embase, Cancerlit, Scisearch, Biosis; BRS-EAST: USPatroll, search terms: L49, antibody, single chain antibody, scfv, sfv, modified, mutated	, POPulos, EPO, 1PO, Derwini I, fusion, fused, chimeric, adept
biattog-medine, Embase, Cancerlit, Scisearch, Biosis; BRS-EAST: USPatroll, search terms: L49, antibody, single chain antibody, scfv, sfv, modified, mutated	, PGPuos, EPO, 1PO, Derwini I, fusion, fused, chimeric, adept
biattog-medime, Embase, Cancerlit, Scisearch, Biosis; BRS-EAST: USPatfull, search terms: L49, antibody, single chain antibody, scfv, sfv, modified, mutated	, PGPuos, EPO, 1PO, Derwini I, fusion, fused, chimeric, adept
bialtog-medine, Embase, Cancerlit, Scisearch, Biosis; BRS-EAST: USPatfull, search terms: L49, antibody, single chain antibody, scfv, sfv, modified, mutated	, PGPuos, EPO, 1PO, Derwin I, fusion, fused, chimeric, adept
bialtog-medine, Embase, Cancerlit, Scisearch, Biosis; BRS-EAST: USPatfull, search terms: L49, antibody, single chain antibody, scfv, sfv, modified, mutated	, POPulos, EPO, 1PO, Derwing
biattog-medine, Embase, Cancerlit, Scisearch, Biosis; BRS-EAST: USPatroll, search terms: L49, antibody, single chain antibody, scfv, sfv, modified, mutated	, PGPubs, EPO, 1PO, Derwing
DIALUG-Medline, Embase, Cancerlit, Scisearch, Biosis; BRS-EAST: USPatroll, search terms: L49, antibody, single chain antibody, scfv, sfv, modified, mutated	, PGPubs, EPO, 1PO, Derwini I, fusion, fused, chimeric, adept
bialog-medine, Embase, Cancerlit, Scisearch, Biosis; BRS-EAST: USPatroll, search terms: L49, antibody, single chain antibody, scfv, sfv, modified, mutated	, PGPubs, EPO, 1PO, Derwini I, fusion, fused, chimeric, adept
	, PGPuos, EPO, 1PO, Derwini I, fusion, fused, chimeric, adept
	, PGPuos, EPO, 1PO, Derwini I, fusion, fused, chimeric, adept
	, PGPuos, EPO, 1PO, Derwin L, fusion, fused, chimeric, adept
	, PGPuos, EPO, 1PO, Derwini L, fusion, fused, chimeric, adept
	, PGPuos, EPO, 1PO, Derwini L, fusion, fused, chimeric, adept
	, PGPuos, EPO, 1PO, Derwini I, fusion, fused, chimeric, adept
	, Portus, EPO, 1PO, Derwin I, fusion, fused, chimeric, adept
	, Portus, EPO, 1PO, Derwin L, fusion, fused, chimeric, adept
	, Portus, EPO, 1PO, Derwin L, fusion, fused, chimeric, adept
	, Portios, EPO, IPO, Derwini I, fusion, fused, chimeric, adept
	, Portus, EPO, PO, Derwin L, fusion, fused, chimeric, adept
	, Portus, EPO, 1PO, Derwing I, fusion, fused, chimeric, adept
	, Portus, EPO, PO, Derwing, Rusion, fused, chimeric, adept
	, Portus, EPO, PO, Derwing, Rusion, fused, chimeric, adept
	, POPulos, EPO, IPO, Derwing L, fusion, fused, chimeric, adept
	, Portus, EPO, PO, Derwin L, fusion, fused, chimeric, adept

Form PCT/ISA/210 (second sheet) (July 1998)